epilepsy

[The University of Texas at San Antonio] Brain and stem cell researchers from The University of Texas at San Antonio have secured $12.5 million in funding over five years from the National Institutes of Health through the NIH BRAIN Initiative to advance new methods for studying genetic brain disorders.

[Stem Cell Research] Scientists generated iPSCs from a normal individual by electroporation of peripheral blood mononuclear cells, and further generated a SCN1B-knockout human iPSC line via CRISPR/Cas9 gene editing.

[Molecular Psychiatry] Investigators used iPSC technology to obtain hippocampal neurons to investigate the neuropathology of IQSEC2-mediated disease. The neurons were characterized at three-time points during differentiation to assess developmental progression.

[Vyant Bio, Inc.] Vyant Bio, Inc. and Cyclica, Inc. announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder, a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.

[Monash University] Monash epilepsy researchers are on an Medical Research Future Fund (MRFF) grant to personalise epilepsy anti-seizure treatment with brain organoids and artificial intelligence. Enabling innovative research that cuts across multiple scientific and clinical disciplines in order to address urgent unmet health care needs is what the Medical Research Future Fund scheme was designed to do, and is doing exactly that with its recently announced funding for a project to help patients with epilepsy.

[NeuroPace, Inc.] NeuroPace, Inc., announced the broad launch of its nSight Platform, an online portal that helps physicians provide more personalized, data-driven epilepsy care by enabling them to remotely review patient progress, discover actionable insights, and track their clinic’s overall patient outcomes.